Sol Gel Technologies Ltd (NASDAQ:SLGL)
| 4.15 Delayed Data As of 2:24pm ET |  -0.115 / -2.70%Today’s Change | 3.24 Today|||52-Week Range 7.95 | -8.99% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $102.5M |
Company Description
Sol-Gel Technologies Ltd. is a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.
Contact Information
Sol-Gel Technologies Ltd. Weizmann Science Park Ness Ziona Tel Aviv 74036 |
Employees
Shareholders
| Other institutional | 20.72% |
| Mutual fund holders | 1.96% |
| Individual stakeholders | -- |
Top Executives
| Alon Seri-Levy | Chief Executive Officer & Director |
| Itzik Yosef | Chief Operating Officer |
| Gilad Mamlok | Chief Financial Officer |
| Ofer Toledano | Vice President-Research & Development |
| Ofra Levy-Hacham | VP-Clinical & Regulatory Affairs |
